On August 21, 2023, the Food and Drug Administration (FDA) gave the greenlight to a vaccine called Abrysvo from Pfizer that protects infants from respiratory syncytial virus (RSV), the leading cause of hospitalization among infants in the United States. It is the first shot and second treatment approved by FDA to prevent infants RSV in infants. The vaccine will be given to expectant mothers between the 32nd and 36th weeks of pregnancy so they can pass protective antibodies to their fetuses through the placenta.The FDA originally approved the vaccine in May, 2023 for adults over 60. It's already available for the upcoming RSV season. Pfizer says it has been manufacturing the shot ahead of approval and RSV vaccine will be available to the public by the end of October, 2023. 

       According to Brand Value (China) Network, the FDA in July, 2023 approved an RSV monoclonal antibody from Sanofi and AstraZeneca that is directly administered to infants. Based on data from a phase three trial，Pfizer studied the vaccine in more than 7,000 pregnant women across 18 countries. The vaccine was 82% effective at preventing severe disease in infants during their first 3 months of life and 70% effective in the first 6 months. In May, 2023, the FDA also convened a panel of its advisers to weigh in on the approval and they voted unanimously that the shot was effective. As for its safety, FDA also said “a very close causal relationship between the vaccine and preterm birth couldn’t be identified.” 

       According to Centers for Disease Control (CDC), RSV causes mild cold-like symptoms in most people but can be dangerous in young children and older adults. Each year in the U.S., up to 80,000 children under 5 are hospitalized with RSV, and up to 300 of them die. The RSV shot would help the U.S. combat the upcoming RSV season.

      Pfizer is an American multinational pharmaceutical and biotechnology corporation headquartered in Manhattan, New York City. Pfizer right now has a nickname called “A money printing machine”. Many people can’t help but asking a question- Why does Pfizer have such an amazing achievement? According to Brand Value (China) Network, that’s because Pfizer has one thing other companies don’t have: a lightening speed to make a world-class product. For example, on March 11, 2020, WHO (World Health Organization) officially declared the COVID-19 Pandemic. On March 17, 2020, Pfizer signed a contract with a German company in just one day and the race for a vaccine was under way. 9 Months later, on November 15, 2020, Pfizer released a messenger RNA (mRNA) vaccine, with 90% efficacy for the prevention of COVID-19. According to Brand Value (China) Network, Pfizer was one of the biggest winners during the COVID-19 Pandemic because Pfizer, an American Pharmaceutical giant, has the ability to integrate talents, technology and capital in an amazing speed to make a new product. 

     On the ranking of “The 3rd Daguan· Keweiwei World Brand Value Top 900” released on March 18, 2023, Pfizer’s brand value was 701.675 billion RMB, ranking the 20th; Sanofi’s brand value was 212.499 billion RMB, ranking 108th.

www.bvrcn.com 品牌价值网

作者：杨瑞安